Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever

Genetics and Molecular Research

Volumn 12, Issue 3, 2013, Pages 3521-3528

  Dogruer, D ^a   Tug, E ^b   Bes, C ^a   Soy, M ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Colchicine; CYP3A4; Familial Mediterranean fever; P gp MDR1; Pharmacogenetics

Indexed keywords

COLCHICINE; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYP3A4 GENE; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG RESPONSE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; MDR1 GENE; PHARMACOGENETICS; SEX DIFFERENCE; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; COLCHICINE; CYTOCHROME P-450 CYP3A; FAMILIAL MEDITERRANEAN FEVER; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TURKEY; YOUNG ADULT;

EID: 84884573185     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.January.24.2     Document Type: Article

References (33)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39: 361-398.
2. Brinkmann U and Eichelbaum M (2001). Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1: 59-64.
3. Cocco G, Chu DC and Pandolfi S (2010). Colchicine in clinical medicine. A guide for internists. Eur. J. Intern. Med. 21: 503-508.
4. Cummins CL, Jacobsen W and Benet LZ (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300: 1036-1045.
5. Du J, Xing Q, Xu L, Xu M, et al. (2006). Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7: 831-841.
6. Dvorak Z, Modriansky M, Pichard-Garcia L, Balaguer P, et al. (2003). Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol. 64: 160-169.
7. Evans WE and McLeod HL (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348: 538-549.
8. Ferron GM, Rochdi M, Jusko WJ and Scherrmann JM (1996). Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36: 874-883.
9. Fonnesu C, Cerquaglia C, Giovinale M, Curigliano V, et al. (2009). Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 76: 227-233.
10. Goto M, Masuda S, Saito H, Uemoto S, et al. (2002). C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12: 451-457.
11. Hasler JA (1999). Pharmacogenetics of cytochromes P450. Mol. Aspects Med. 20: 12-137.
12. Hesselink DA, van Schaik RHN, van der Heiden IP, van der Werf M, et al. (2003). Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74: 245-254.
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97: 3473-3478.
14. Hosohata K, Masuda S, Yonezawa A, Katsura T, et al. (2009). MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res. 26: 1590-1595.
15. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, et al. (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72: 314-321.
16. Kim RB, Leake BF, Choo EF, Dresser GK, et al. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70: 189-199.
17. Kimura Y, Morita SY, Matsuo M and Ueda K (2007). Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98: 1303-1310.
18. Lamba J, Strom S, Venkataramanan R, Thummel KE, et al. (2006). MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79: 325-338.
19. Lange U, Schumann C and Schmidt KL (2001). Current aspects of colchicine therapy-classical indications and new therapeutic uses. Eur. J. Med. Res. 6: 150-160.
20. Marzolini C, Paus E, Buclin T and Kim RB (2004). Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75: 13-33.
21. Molad Y (2002). Update on colchicine and its mechanism of action. Curr. Rheumatol. Rep. 4: 252-256.
22. Nebert DW and Russell DW (2002). Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
23. Niel E and Scherrmann JM (2006). Colchicine today. Joint Bone Spine 73: 672-678.
24. Ozdemir V, Kalow W, Tang BK, Paterson AD, et al. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10: 373-388.
25. Pras E, Livneh A, Balow JE, Jr., Pras E, et al. (1998). Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am. J. Med. Genet. 75: 216-219.
26. Shimada T, Yamazaki H, Mimura M, Inui Y, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423.
27. Tateishi T, Soucek P, Caraco Y, Guengerich FP, et al. (1997). Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem. Pharmacol. 53: 111-116.
28. Terkeltaub RA (2009). Colchicine update: 2008. Semin. Arthritis Rheum. 38: 411-419.
29. Tufan A, Babaoglu MO, Akdogan A, Yasar U, et al. (2007). Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J. Rheumatol. 34: 1540-1544.
30. Turolo S, Tirelli AS, Ferraresso M, Ghio L, et al. (2010). Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol. Rep. 62: 1159-1169.
31. Vicente J, Sinues B, Fanlo A, Vasquez P, et al. (2008). Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. Mol. Biol. Rep. 35: 473-478.
32. Westlind A, Lofberg L, Tindberg N, Andersson TB, et al. (1999). Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun. 259: 201-205.
33. Zhou SF (2008). Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.